MGS0008

MGS0008 is an orally active and brain-penetrant metabotropic glutamate receptor 2/3 (mGlu2/3) agonist with EC50 values of 29.4 nM and 45.4 nM for mGluR2 and mGluR3, respectively. MGS0008 is promising for research of central nervous system disorders, including schizophrenia, anxiety, and neurodegenerative diseases[1][2].

Product Specifications

CAS Number

[234085-20-2]

UNSPSC

12352211

Hazard Statement

H302-H315-H319-H335

Target

MGluR

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Smiles

O=C([C@@]1(N)[C@]2([H])[C@@H](C(O)=O)[C@]2([H])C[C@@H]1F)O

Molecular Formula

C8H10FNO4

Molecular Weight

203.17

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Ochi M, et al. Bottom-up physiologically based pharmacokinetic modelling for predicting the human pharmacokinetic profiles of the ester prodrug MGS0274 and its active metabolite MGS0008, a metabotropic glutamate 2/3 receptor agonist. Xenobiotica. 2022 Feb;52 (2) :119-128.|[2]Nakazato A, et al. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J Med Chem. 2000 Dec 14;43 (25) :4893-909.